Mr. Wang is 27 years old, is a private enterprise business backbone, has been very hard, no one knows that his liver has a problem; his parents, although he knows that he is a “small triple yang”, but has not been concerned about the results of his examination; and he himself, in addition to the drugstore to buy their own medication to eat, almost did not carry out any formal treatment. Until his liver discomfort to the hospital for examination, for his physical examination of the doctor ate a shock: liver tumor almost occupied his entire liver, and even began to oppress other organs. From the time he was diagnosed with liver cancer to the time he passed away, it was only a short month. If he had gone to the hospital earlier, he would not have sent his parents to their deaths in vain. Hepatitis B virus, since its discovery in the 1960s and 1970s, has become the greatest threat to human health. According to some figures, the number of people infected with the hepatitis B virus worldwide has exceeded 350 million, and about 1 million people lose their lives every year as a result. China is also one of the countries most heavily shadowed by Hepatitis B. There are about 90 million people chronically infected with the Hepatitis B virus, almost 7% of the country’s population, but only 1% of these patients are receiving treatment. At the recent 17th National Conference on Viral Hepatitis and Liver Diseases, Prof. Po-Lin Chan, Senior Advisor to the World Health Organization (WHO) Office in China, warned that 3 out of every 10 chronically infected people in China will develop life-threatening complications such as cirrhosis and liver cancer as a result. If we do nothing, about 9 million people in China will die of hepatitis-related diseases in the next 15 years. ” Hepatitis B virus is most likely to cause liver cancer “Clinicians have found that there are many patients with hepatitis B, the onset of the disease, is an insidious onset of the process, it is not as we traditionally think, after a jaundice, after a very typical hepatitis attack of the symptoms. Therefore, many patients may have developed hepatitis B, but they are not aware of it, and it is only after they have progressed to cirrhosis, or even liver cancer, that they find out that they have been infected with hepatitis B when they go back for examination. Therefore, for those who have a history of hepatitis B, it is especially important to have regular checkups. It has been clinically proved that 80% of liver cancer patients are caused by the transmission of hepatitis B virus. In some people, all the family members are Hepatitis B patients, and the mother-child blood channel passes the Hepatitis B virus to their daughters, who then pass the Hepatitis B virus to the next generation from the mother-child blood channel after marriage, while the Hepatitis B virus of the husband comes from the sexual life with his wife. This phenomenon of common sense and unconscious transmission has led to quite a number of liver cancer families nowadays. It is due to various comprehensive reasons, such as economically backward areas, the people’s poor awareness of cancer prevention and very poor knowledge of cancer prevention, thus resulting in familial liver cancer, which needs to be taken seriously. According to the survey, 10% to 20% of hepatitis B virus infected patients may turn into chronic hepatitis B, 10% to 20% of chronic hepatitis B patients will turn into cirrhosis, and 10% to 20% of cirrhosis patients may develop into liver cancer. This performance to both doctors and patients have knocked an alarm, hepatitis B patients must be timely standardized treatment, otherwise the distance from liver cancer may be just a step away! Only scientific and standardized treatment can effectively prevent hepatitis B from turning into liver cancer. Otherwise, if left unchecked, the continuous infection and replication of hepatitis B virus and the fibrotic lesions prompted by the inflammatory response will inevitably lead to cirrhosis and even liver cancer. ” Some patients with hepatitis B can achieve clinical cure “Because China is a high incidence of hepatitis B, many virus carriers do not develop the disease throughout their lives. Therefore, some patients with chronic hepatitis B who should be treated mistakenly believe that “antiviral treatment is irrelevant” and “taking some enzyme-lowering drugs when liver function is abnormal will do”. These patients are reluctant to seek medical treatment for a long time, and are unwilling to listen to the systematic treatment of doctors, and even give up the regular monitoring of liver function and virological indexes, and once the condition is serious and they have to seek medical treatment, they often have already developed into severe hepatitis or advanced stage of cirrhosis. It is true that some hepatitis B virus carriers can remain disease-free for a lifetime. However, hepatitis B virus damage to the human body is often carried out quietly in the body, most patients with chronic hepatitis in the mild elevation of aminotransferases do not have obvious symptoms. Unlike a cold, fever or diarrhea, patients cannot tell if they should be treated based on their symptoms. Therefore, we often say that the hepatitis B virus is a lurking “secret agent” in the body, and people infected with hepatitis B virus should always be vigilant and regularly check liver function and hepatitis B virology indicators in the hospital, and once abnormalities are detected, they should immediately seek medical treatment and undergo antiviral therapy according to the doctor’s treatment plan. China’s newly released 2015 Guidelines for the Prevention and Control of Chronic Hepatitis B (hereinafter referred to as the Guidelines) suggests that the overall goal of chronic hepatitis B treatment is to maximize long-term suppression of the hepatitis B virus, reduce hepatocellular inflammation and necrosis as well as hepatic fibrosis, and to delay and reduce the occurrence of cirrhosis, hepatocellular carcinoma and their complications, so as to improve the quality of life and prolong the survival time. The new version of the Guidelines emphasizes for the first time that clinical cure of chronic hepatitis B should be pursued as far as possible for some suitable patients, i.e., persistent undetectable hepatitis B virus DNA in serum and disappearance of hepatitis B surface antigen after stopping the treatment, accompanied by return of normalization of ghrelin transaminase and changes in liver histology. Many people are aware of the medical common sense that there is a difference in efficacy between drugs, some high and some low, and that the body can develop resistance to drugs. Although the guidelines for hepatitis B in various countries clearly emphasize that low-resistant drugs should be used as the first choice of hepatitis B treatment drugs, but in China, there are still 60% to 70% of hepatitis B patients using high-resistant drugs, especially in the second- and third-tier cities and rural areas; these drugs are often prone to drug-resistance, affecting the overall efficacy of antiviral therapy. In Japan, South Korea, the United States and Europe, more than 70% of hepatitis B patients are treated with potent, low-resistance first-line antiviral drugs. This new version of the Guidelines clearly states that potent and low-resistant representative drugs are the preferred oral medications for patients with chronic hepatitis B in primary treatment, while high-resistant drugs are not recommended. ” Why is hepatitis B prone to recurrence ” Many patients are distressed by the recurrence of hepatitis B. They have obviously gone through a long period of time to cure hepatitis B disease, and did not expect the disease to recur after a period of time. In that case, the positive treatment they have carried out in the early stage will not be in vain. What affects the recurrence of hepatitis B? Alcohol consumption is one of the most common causes of hepatitis B recurrence. Wine oxidizes in the liver and forms the harmful substance acetaldehyde, which can directly damage the liver, so hepatitis patients must abstain from alcohol. Unauthorized use of medication is also a common cause of hepatitis B recurrence. Some patients are eager to get well, and apply “liver protection”, “enhance immunity”, “strong liver” medicine without authorization; some gullibly believe in advertisements, and keep taking all kinds of so-called “turnaround” medicines with doubtful efficacy. “Some people believe in the advertisements and keep taking the so-called so-called drugs of doubtful efficacy. They do not understand that some drugs themselves have hepatotoxicity, more abuse will cause liver damage. In hepatitis patients, 10% to 20% for drug liver disease, according to statistics, there are 500 to 1,000 kinds of drugs can cause liver injury. Some patients do not follow the doctor’s instructions. In the treatment of arbitrary stopping, omission or additional service, some people think that this has nothing to do. But I don’t know that antiviral drugs need to be taken for a long time, according to the doctor’s instructions to ensure that the condition does not rebound. In addition, mixed infections are also prone to cause recurrent hepatitis B attacks. Hepatitis B patients can be infected with hepatitis C. Hepatitis C infection occurs in about 10% of chronic hepatitis B. Hepatitis B virus is suppressed and hepatitis C virus may be activated. Hepatitis D virus is a defective virus that must rely on the HBSAG of the hepatitis B virus to replicate, and sometimes infects the body at the same time as the hepatitis B virus. Certain “non-hepatophilic viruses” such as cytomegalovirus, EBV, coxsackievirus, herpesvirus, etc. can also infect hepatitis B patients, causing the transaminases to rise again. ” Vaccines are the most effective way to prevent hepatitis B” The hepatitis B vaccine was formed in 1986, and in order to get the hepatitis B vaccine, researchers went from studying replicating viruses, all the way to studying purified protein sequences, and went through a great deal of induced immune responses. In 1991, the vaccine was applied to high-risk groups. Mainly some children, as the infection rate in children is extremely high. In 2005, routine vaccination was introduced in the U.S., where all children who had not been vaccinated against hepatitis B were given the vaccine. The development of hepatitis B vaccine has gone through blood-borne and genetically engineered vaccine stages. The technology of genetically engineered hepatitis B vaccine has been quite mature, and the vaccine developed by China itself has proved to be safe and effective after years of observation and has been approved for production. The development and application of hepatitis B vaccine will play an important role in the prevention and control of hepatitis B. Humans are the most vulnerable to hepatitis B virus. Humans are the only host of hepatitis B virus. When safe, effective and sufficient amount of hepatitis B vaccine is available for vaccination, it will certainly play a decisive role in controlling the spread of hepatitis B virus. The World Health Organization recommends that all infants be vaccinated against Hepatitis B as soon as possible after birth (preferably within 24 hours), and our Hepatitis B vaccination procedure is to administer one dose each at 0, 1 and 6 months of age. After completing the vaccination program on time, 95% of infants can produce protective antibody levels. Protection lasts for at least 20 years and may even be lifelong. Adults also receive the hepatitis B vaccine in 3 doses: a second dose 4 weeks after the first dose, and a third dose 5 months after the second dose. If you have not received the hepatitis B vaccine, or have not received the full dose, or if your vaccination history is unknown, you can get vaccinated. There is no need for prior serologic screening before vaccination, and the hepatitis B vaccine is safe for both infected and uninfected individuals. Why is the hepatitis B vaccine effective in preventing hepatitis B? The Hepatitis B vaccine is actually a preparation of certain active proteins on the surface of the Hepatitis B virus. When these proteins are inoculated into the human body, the immune cells produce “specific weapons” (antibodies) to fight the Hepatitis B virus, and the inoculated person is not infected himself/herself. When the human body comes into contact with the hepatitis B virus again, the “specific weapons” that have already existed in the body will immediately “fire” to clear the virus and fight against the infection, thus avoiding the occurrence of hepatitis B.